Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Revlimid lenalidomide: Phase III data

An open-label, Italian Phase III trial in 402 patients with newly diagnosed MM showed that Revlimid plus melphalan and prednisone led to a median PFS of 24 months vs. 38

Read the full 301 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE